Dr. Pankaj Taneja

About

Dr. Pankaj Taneja is eminent teacher and scientist. He has 20 years of experience at national and international levels in biotechnology. His area of research is in  signal transduction pathways in cancer prevention.  He was also awarded with prestigious presidential Ramalingaswamy fellowship.He worked as postdoc fellow and Scientist  in Johns Hopkins and Wake Forest Universities, USA.

Experience

20 years

• Ramalingaswamy fellow DBT and INMAS(2011-2016)
• Scientist and Research Assistant Professor, Wake Forest University, USA (2005-2010)
• Post Doctoral fellow, Johns Hopkins University, USA (2003-2005)
• Research fellow and Lecturer (1998-2003) IITR Lucknow and Hamdard University, Delhi

Qualification

• PhD - 2003 from Hamdard University
• M.Sc- 1998 from Hamdard University
• Ramalingaswamy fellow

Award & Recognition

• Awarded Presitigious Presidential Ramalingaswamy fellowship and grant (Rs. 74.5 Laks Total) from DBT CGO Complex Delhi 
• Invited Visiting Scientist (June-August 2015), Radiation Oncology Division, University of Florida, USA.Guest editor  of "Journal Alternative and Complementary Medicine in radiation pathologies" Hindwai Publications 2014, Egypt, UK and USA
• Consultant 2012; Nutrametrix Health Solutions, USA
• Certified Course on Occupational and Enviromental Medicine  Johns Hopkins School of Public Health; 2004
• Supervised & Taught various Summer Interns, Grad& Post Grad students in their project training in Wake Forest, Johns Hopkins & Hamdard  Universities.
• Awarded Best paper in the XXVII^th Annual Conference of Environmental Mutagen Society of India entitled “ Antigenotoxic potential of diallyl sulfide a mechanistic approach”2002
• Selected trainee for Genotoxicity evaluation in Central Drug Research Institute, Lucknow India, 1999
• Selected Fellow award for Antigenotoxic evaluation of Plant Phenolics, ITRC, Lucknow India2004

Reviewer of  manuscript of scientific  journals-

• Investigational New Drugs
• Food and Chemical Toxicology
• Journal of Agricultural Food Chemistry
• Molecular Carcinogenesis 
• Cancer Biology and Therapy
• Cancer chemotherapy and Pharmacology
• Environmental Monitoring and Assessment

Research

• Gulzar M, Syed SB, Khan FI, Khan P, Ali, S Hasan GM, Taneja P, Hassan I(2019). Elucidation of interaction mechanism of ellagic acid to integrin linked kinase. International Journal of Biological Macromolecules. 122: 1297-1304.
• Mallakin A, Taneja P, Inoue, K, Ward AN, Dahms H-U (2018). Biochemical characterization of ratfish (Chimaera montrosa) liver oil; Cytotoxic and antineoplastic evaluation in cancer cell lines. Integrative Clinical Medicine 2(4): 1-11.
• Tripathi S, Taneja P, Jha SK (2018). Training on an Appetitive (delay)-conditioning task enhances Oscillatory waves during sleep in the cortical and amygdalar network. Frontiers in Behavioural Neuroscience. 12 (260): 1-17.
• Rattan SS, Taneja P (2018). Revealing the J-coupling in the H-NMR Spectra of antineoplastic and antimetabolites drugs. Der Pharma Chemica 10(1): 55-58.
• Gulzar M, Ali S, Khan FI, Khan P, Taneja P, Hassan I (2018). Binding mechanism of Caffeic acid and simvastatin to the integrin linked kinase for therapeutic implications: a comparative docking and MD simulation studies. Journal of Biomolecular Structure and Dynamics 29: 1-37.
• Rattan S, Taneja P. (2018). Revealing the J-coupling in the 1H-NMR Spectra of Antineoplastic and Antimetabolites Drugs. Der Pharma Chemica, 10(1) 50-53
• Onwurah C, Majumder S and Taneja P (2017). Growth Characteristics of Indian and Nigerian Chlorella pyrenoidosa used as Food Supplement. Biotech. BioSc. Res. Asia 14(2) 835-841
• Fry Taneja P, EA, Inoue K (2016). Oncogenic and tumor suppressive mouse models of breast cancer engaging Her2/Neu. Int. J.Cancer. Aug 23. doi 10.1002/ijc.30399.
• Khan AR, Taneja P(2016). In vivo inhibition of Glutathione-S-transferaseP1 by Bovine Lactoferricin in Swiss Albino tumor bearing mice. Journal of App. Pharm Sci 6(11). 210-213.
• Khan AR, Sadiq IZ, Abdulahi LI, Danlam D, Taneja P (2016). Chemopreventive role of Bovine Lactoferrcin against 7,12 Dimethlyl Benz anthracene induced skin cancer in female swiss albino mice. Int. J. Pharm Pharmaceut. Sci . 8(8); 215-222.
• Shivam K, Khan AR, Taneja P(2016). Development in diagonosis and treatement Alzheimer,s disease. IOSR J. Pharmacy 6(7) 43-50.
• Khan AR, Taneja P. (2015). Cationic Peptide LactoferricinB inhibits Glutathione-  transferase P1 from human placenta and breast cancer cell line MDA MB-231 in  preventing anticancer drug metabolism. Int. J. Pharm Pharmaceut. Sci . 7(8); 1-4.
• Maglic D, Stovall DB, Cline JM, Fry EA, Mallakin A, Taneja P, Caudell DL, Willingham MC, Sui G, Inoue K. (2015). DMP1β, a splice isoform of the      tumour suppressorDMP1 locus, induces proliferation and progression of breast  cancer. J Pathol.236(1); 90-102
• Taneja P, Gulzar M and Taneja P. (2015). Phytochemicals in therapy of radiation induced damage and cancer. (Accepted )SM group Publications, Irvin, Texas, USA
• Yadav AK, Vashishta V, Joshi N, Taneja P (2014). AR-A 014418 Used against GSK3beta Downregulates Expression of hnRNPA1 and SF2/ASF Splicing Factors. J Oncology.695325. doi 10.1155/2014/. Epub  Jan 2.
• Fry EA, Taneja P, Maglic D, Zhu S, Sui G, Inoue K. (2013) Dmp1α inhibits HER2/neu-induced mammary tumorigenesis. PLoS One. ;8(10)e77870.
• Zhu S, Mott RT, Fry EA, Taneja P, Kulik G, Sui G, Inoue K. (2013). Cooperation betweenDmp1 loss and cyclin D1 overexpression in breast cancer. Am J Pathol. 183(4)1339-50.
• Inoue K, Fry EA, Taneja P. (2013). Recent progress in mouse models for tumor suppressor genes and its implications in human cancer.Clinical Medical Insights Oncology. 7; 103-122.
• Maglic D*, Zhu S*, Fry E*, Taneja P*, Kai F, Kendig RD, Sugiyama T, Miller LD, Willingham M, Inoue K. (2012). Prognostic value of hDMP1-Arf-hDM2-p53 pathway in breast cancer. Oncogene Oct8, 1-10 * Equal Contribution
• Taneja P, Zhu S, Maglic D, Fry E, Kendig R, Inoue K (2011). Transgenic and Knockout mice models to reveal the functions of tumor Suppressor genes. Clinical Medical Insights Oncology. 5; 235-257.
• Taneja P, Maglic D, Sugiyama T, Kai F, Frazier D.P, Kendig R.D,Willingham S,  Inoue K.(2010). Dmp1 is the critical regulator of Her2/Neu P53-Arf signaling. Cancer Research 70;9084-9094.
• Taneja P, Maglic D, Sugiyama T, Kai F, Zhu S, Kendig R.D, Fry E,  Inoue K.(2010). Classical and novel prognostic markers of breast cancer and their clinical significance. Clinical Medical Insights Oncology 4 15-34.
• Mallakin A, Sugiyama T,  Kai F, Taneja P, Frazier D, Maglic D Kendig R, Inoue K. (2010).The Arf inducing transcription factor Dmp1 encodes transcription regulator Amphiregullin, Thrombospondin1 and JunB. Int J Cancer ,126; 1403-1416.
• Taneja P, Sugiyama T, Kai F, Frazier D.P, Kendig R.D, Maglic D, Taneja N.K, Inoue K. (2009). MMTV mouse models for human breast cancer and their diagnostic values. Expert Reviews Mol Diag.  9 (5),423-440.
• Prasad S, Taneja P, George S, Shukla Y (2009). Regulation of Cell Signalling molecules by Natural compoundsChemopreventive and Chemotherapeutic Approach.Cancer Therapy. 7, 467-487.
• Sugiyama T, Taneja P, Frazier DP, Kendig RD, Morgan RL, Matise LA, Lagedrost SJ, Inoue K. (2008) Oncogenic and non-oncogenic signaling pathways that regulate Dmp1 (Dmtf1) (review).Clinical Medicine Oncology,2, 209-219.
• Inoue K, Sugiyama T, Taneja P, Morgan RL, Frazier DP. (2008) Emerging roles of DMP1 in lung cancer. Cancer Research, 68, 4487-4490.
• Taneja P, Mallakin A, Matise LA, Frazier DP, Choudhary M, Inoue K. (2007) Repression of Dmp1 and Arf transcription by anthracyclins critical roles of the NF-kappaB subunit p65. Oncogene, 26,7457-7466.
• Mallakin A*, Sugiyama T*, Taneja P*, Matise LA*, Frazier DP, Choudhary M, Hawkins GA, D'AgostinoRB Jr, Willingham MC, and Inoue K. (2007) Mutually exclusive inactivation of DMP1 and Arf/p53 in lung Cancer. Cancer Cell, 12, 381-394.
• * Equal Contribution
•  Mallakin  A, Taneja P, Matisie A , Willingham M, Inoue K. (2006) .Expression of Dmp1 in specific differentiated, non-proliferating cells and its regulation by E2Fs. Oncogene,25, 7703-7713.
•  Shukla Y, Taneja P, Arora A, Sinha N (2004). Mutagenic Potential of  Mancozeb in Salmonella typhimurium. J Env Pathol. Toxicol. Oncol 23, 294-302.
• Taneja P, Arora A, Shukla Y. (2003).Antimutagenic effects of black tea in the Salmonella typhimurium reverse mutation assay .Asian. Pac. J Cancer Prev. 4, 193-198.
• Shukla Y, Arora  A, Taneja P. (2003). Antigenotoxic potential of certain dietary constituents. Teratogen. Carcinogen. Mutagen. 23,323-335.
• Shukla Y, Taneja P (2002). Anticarcinogenic effect of   black tea on pulmonary tumors in Swiss albino mice. Cancer Lett., 176, 137-141
• Shukla  Y, Arora  A, Taneja P, (2002). Antimutagenic potential of Curcumin on Chromosomal aberrations in Wistar rats. Mutat. Res. 515,197-202.
• Shukla Y, Taneja P. (2002). Antimutagenic effect of garlic extract on Chromosomal aberrations. Cancer Lett 176, 31-36. 
• Shukla Y, Taneja P.(2002) Mutagenic evaluation of cypermethrin in mouse dominant lethal assay.J Env Pathalog Toxicol. Onclol., 21, 259-265.
• Shukla Y, Taneja P (2001) Antimutagenic effect of black tea extract using” rodent dominant lethal mutation assay. Toxicology, 168, 269-274
• Shukla, Y., Taneja, P (2000). Mutagenic evaluation of deltamethrin using rodent dominant lethal assay. Mutat. Res, 467, 119- 127
•  BOOK CHAPTERS
• Taneja P, Frazier DP, Sugiyama T, Lagedrost S, Inoue K. (2008). Control of cellular physiology by transcription factors E2F and their roles in carcinogenesis. Research Signpost. (Review). ISBN 978-81-308-0230-5; Pages-179-197.
• Taneja P, Kendig R, Zhu S, Maglic D, Fry S, Inoue K. (2012). Oncogenes and Tumor Suppressor genes in Small Cell Lung Carcinoma. Lung Diseases-Selected state of art Reviews INTECH; ISBN 978-953-51-0180-2; Pages 148-170

Area of Interest

• Signal transduction and genetic toxicology